SG/CALL/GILEAD SCIENCES/90/0.1/21.06.24 Stock

SG/CALL/GILEAD SCIENCES/90/0.1/21.06.24 Share Price

Warrant

DE000SQ4FJF0

End-of-day quote Deutsche Boerse AG
- ^EUR	-

6 months	-99.58%
Current year	-99.52%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart SG/CALL/GILEAD SCIENCES/90/0.1/21.06.24

Latest news about GILEAD SCIENCES, INC.

Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup	15/06	DJ
EU regulator mandates label updates on CAR-T cancer therapies	14/06	RE
Gilead Sciences' Kite Unit Reports Positive Data From New Analyses of Yescarta	14/06	MT
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment	14/06	BU

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Société Générale
WKN	SQ4FJF
ISIN	DE000SQ4FJF0
Date issued	16/11/2022
Strike	90 $
Maturity	21/06/2024 (5 Days)
Parity	10 : 1
Emission price	0.89 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Spread	0.019 €
Spread %	95.00%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company